Hypothesis

Early senescent β‑cells act as chaperones by releasing exosomes enriched in LIF, HSPA5 (BiP) and pro‑autophagic miRNAs that bolster UPR resilience in adjacent β‑cells. When stress becomes chronic, the exosomal cargo shifts toward pro‑inflammatory SASP factors and miR‑34a, erasing the protective signal. Consequently, senolytic clearance removes both adaptive and maladaptive exosomes, but the loss of the early‑phase chaperone vesicles unmasks latent proteotoxic stress, accelerating β‑cell failure.

Mechanistic premise

• p21‑driven senescence is triggered early when UPR sensors (Atf6α or Ire1α) are overwhelmed, linking proteostatic stress to a transient senescence program.[1][2]
• p21 directly up‑regulates RAB27A, a key regulator of exosome biogenesis, increasing secretion of LIF‑containing vesicles.[5]
• These exosomes deliver HSPA5 and autophagy‑inducing miRNAs (e.g., miR‑30a) to neighboring β‑cells, attenuating PERK‑eIF2α‑CHOP signaling and enhancing clearance of oligomeric IAPP.[4]
• In chronic stress, sustained UPR activation switches the exosomal payload to SASP cytokines (IL‑6, CCL2) and miR‑34a, which suppress SIRT1 and autophagy, promoting paracrine dysfunction.[3]

Testable predictions

1. Isolates of exosomes from early senescent human islets (p21^high, LIF^high) will reduce CHOP expression and improve glucose‑stimulated insulin secretion in naïve β‑cells exposed to IAPP oligomers, whereas exosomes from late senescent islets (p21^low, SASP^high) will have the opposite effect.
2. Genetic or pharmacological inhibition of RAB27A in β‑cells will diminish exosome release, abolish the protective effect of early senescence, and sensitize islets to IAPP‑induced apoptosis despite intact p21.
3. Senolytic treatment (ABT263) administered during the acute phase of IAPP stress will decrease exosome‑mediated HSPA5 transfer, leading to higher ER stress markers and faster loss of β‑cell mass compared with vehicle‑treated controls.

Experimental design

• Islet preparation: Obtain human donor islets; induce senescence acutely with low‑dose tunicamycin (2 h) to generate early senescent cells, or chronically with high‑dose palmitate + cytokines (7 days) for late senescent cells.
• Exosome isolation: Ultracentrifugation of conditioned media; validate by CD63, CD81, and uptake assays using PKH26 labeling.
• Functional assays: Treat naïve rat INS‑1 cells or human islets with IAPP oligomers (5 µM) ± exosomes (10 µg protein). Measure CHOP, BiP, XBP1 splicing, ATP‑linked insulin secretion, and cleaved caspase‑3 by flow cytometry or ELISA.
• Interventions: (a) RAB27A knockdown via siRNA; (b) ABT263 (1 µM) added 24 h before IAPP challenge.
• Readouts: Compare groups using two‑way ANOVA; expect significant interaction between exosome source and stress condition.

If early senescent exosomes are protective and their removal by senolytics exacerbates ER stress, the hypothesis is supported. Conversely, if exosome depletion does not alter IAPP‑induced toxicity, the chaperone‑exosome model would be refuted.

This reframes senolytics not as a blanket clearance strategy but as a timing‑dependent intervention: preserving or augmenting early‑phase exosome release may be preferable to wholesale senocyte ablation in the initial wave of proteotoxic stress.